These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31789892)

  • 1. Letter to the editor re: Cabrera et al., 2019 'The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid'.
    Romach EH; Stanislaus D; Zamek-Gliszczynski MJ
    AIDS; 2020 Jan; 34(1):162-163. PubMed ID: 31789892
    [No Abstract]   [Full Text] [Related]  

  • 2. The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid.
    Cabrera RM; Souder JP; Steele JW; Yeo L; Tukeman G; Gorelick DA; Finnell RH
    AIDS; 2019 Nov; 33(13):1967-1976. PubMed ID: 31259764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir-induced neural tube defects in mice are folate responsive.
    Tukeman GL; Wei H; Lin YL; Wlodarczyk BJ; Finnell RH; Cabrera RM
    AIDS; 2024 Mar; 38(4):439-446. PubMed ID: 37382903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir-induced neural tube defects in mice are folate responsive: Erratum.
    AIDS; 2024 Aug; 38(10):1607. PubMed ID: 38990319
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the editor in re: Mohan et al., 2020 'dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels'.
    Romach EH; Posobiec LM; Bloomer JC; Zamek-Gliszczynski MJ; Stanislaus DJ
    EBioMedicine; 2021 Apr; 66():103335. PubMed ID: 33857900
    [No Abstract]   [Full Text] [Related]  

  • 6. In response to the Letter to the Editor by Romach et al. re our publication "Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels".
    Mohan H; Guzman Lenis M; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
    EBioMedicine; 2021 Apr; 66():103334. PubMed ID: 33862586
    [No Abstract]   [Full Text] [Related]  

  • 7. Déjà vu all over again.
    Saag MS; Dumond JB
    AIDS; 2019 Nov; 33(13):2097-2098. PubMed ID: 31577573
    [No Abstract]   [Full Text] [Related]  

  • 8. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    Taiwo BO; Quiñones-Mateu ME; Smith K; Zheng L; Gulick R; Nyaku AN; Sax PE; Ha B; Kumwenda J; Olefsky M; Godfrey C; Wallis C
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):254-255. PubMed ID: 31914799
    [No Abstract]   [Full Text] [Related]  

  • 9. Bictegravir and dolutegravir: head to head at 96 weeks.
    Barber TJ
    Lancet HIV; 2019 Jun; 6(6):e342-e343. PubMed ID: 31068271
    [No Abstract]   [Full Text] [Related]  

  • 10. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
    Ciccullo A; Dusina A; Lassandro AP; Borghetti A; Baldin G; Di Giambenedetto S
    AIDS; 2020 May; 34(6):956-957. PubMed ID: 32271256
    [No Abstract]   [Full Text] [Related]  

  • 11. Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
    Gelé T; Gouget H; Furlan V; Becker PH; Taburet AM; Lambotte O; Barrail-Tran A
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
    Paparizos V; Vasalou V; Kourkounti S
    Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".
    Walimbwa S; Lamorde M; Waitt C; Amara A; Khoo S
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 31126921
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance to Dolutegravir-A Chink in the Armor?
    Kuritzkes DR
    J Infect Dis; 2018 Jul; 218(5):673-675. PubMed ID: 29617815
    [No Abstract]   [Full Text] [Related]  

  • 15. Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
    Giacomelli A; Conti F; Rusconi S
    EBioMedicine; 2020 Jun; 56():102820. PubMed ID: 32512519
    [No Abstract]   [Full Text] [Related]  

  • 16. Modifying dolutegravir to PrEPare for long life.
    Mandarino A
    Commun Biol; 2022 Nov; 5(1):1193. PubMed ID: 36344610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from dolutegravir and neural tube defects.
    Abrams E; Myer L
    Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
    [No Abstract]   [Full Text] [Related]  

  • 18. Dolutegravir and rat whole embryo culture.
    Copp AJ; Greene NDE; Jao J; Zash R; Mohan H; Dontsova V; Serghides L
    Birth Defects Res; 2022 Jan; 114(1):23-24. PubMed ID: 34851540
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.
    Morse GD
    Clin Infect Dis; 2021 May; 72(10):1823-1825. PubMed ID: 32667998
    [No Abstract]   [Full Text] [Related]  

  • 20. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.